Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Correction

Correction to: The DNA methylation of FOXO3 and TP53 as a blood biomarker of late-onset asthma

Authors: Lin Yuan, Leyuan Wang, Xizi Du, Ling Qin, Ming Yang, Kai Zhou, Mengping Wu, Yu Yang, Zhiyuan Zheng, Yang Xiang, Xiangping Qu, Huijun Liu, Xiaoqun Qin, Chi Liu

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Excerpt

Following publication of the original article [1], the authors would like to correct the Funding section …
Metadata
Title
Correction to: The DNA methylation of FOXO3 and TP53 as a blood biomarker of late-onset asthma
Authors
Lin Yuan
Leyuan Wang
Xizi Du
Ling Qin
Ming Yang
Kai Zhou
Mengping Wu
Yu Yang
Zhiyuan Zheng
Yang Xiang
Xiangping Qu
Huijun Liu
Xiaoqun Qin
Chi Liu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02777-7

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine